102 related articles for article (PubMed ID: 22339906)
1. [Autologous hematopoietic stem cell transplantation following bortezomib-based chemotherapy for one case with POEMS syndrome].
Li LH; Zhang R; Tang XW
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):733. PubMed ID: 22339906
[No Abstract] [Full Text] [Related]
2. [Treatment for POEMS syndrome with subcutaneous administration of bortezomib followed by autologous peripheral blood stem cell transplantation: a case report and literatures review].
Zeng K; Liu ZG; Yang JR; Hou L; Yang YM; Liu T; Niu T
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):550-2. PubMed ID: 23827121
[No Abstract] [Full Text] [Related]
3. Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.
Ishii Y; Yamazaki E; Ishiyama Y; Yamamoto E; Hattori Y; Hagihara M; Tomita N; Ishigatsubo Y
Int J Hematol; 2013 Dec; 98(6):723-8. PubMed ID: 24166587
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
[TBL] [Abstract][Full Text] [Related]
5. Successful bortezomib-based treatment in POEMS syndrome.
Tang X; Shi X; Sun A; Qiu H; Gu B; Zhou H; Xue S; Liu Y; Ruan C; Wu D
Eur J Haematol; 2009 Dec; 83(6):609-10. PubMed ID: 19674063
[No Abstract] [Full Text] [Related]
6. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
Sobas MA; Alonso Vence N; Diaz Arias J; Bendaña Lopez A; Fraga Rodriguez M; Bello Lopez JL
Ann Hematol; 2010 Feb; 89(2):217-9. PubMed ID: 19636554
[No Abstract] [Full Text] [Related]
7. New advances in the diagnosis and treatment of POEMS syndrome.
Li J; Zhou DB
Br J Haematol; 2013 May; 161(3):303-15. PubMed ID: 23398538
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
[TBL] [Abstract][Full Text] [Related]
9. A case of POEMS syndrome treated by autologous hematopoietic stem-cell transplantation.
Créange A; Chater A; Brouet JC; Jaccard A; Rahmouni A; Lefaucheur JP; Santin A
Nat Clin Pract Neurol; 2008 Dec; 4(12):686-91. PubMed ID: 19043425
[TBL] [Abstract][Full Text] [Related]
10. Severe intestinal vasculitis in a patient under treatment with bortezomib.
Mangiacavalli S; Zappasodi P; Castagnola C; Astori C; Varettoni M; Lazzarino M; Corso A
Ann Hematol; 2007 Dec; 86(12):923-4. PubMed ID: 17641890
[No Abstract] [Full Text] [Related]
11. [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
Vokurka S
Klin Onkol; 2010; 23(4):242-4. PubMed ID: 20806822
[TBL] [Abstract][Full Text] [Related]
12. Allografting or autografting for myeloma.
van Rhee F; Crowley J; Barlogie B
N Engl J Med; 2007 Jun; 356(25):2646-8; author reply 2646-8. PubMed ID: 17582078
[No Abstract] [Full Text] [Related]
13. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
14. [New treatment strategy for Crow-Fukase (POEMS) syndrome].
Kuwabara S
Rinsho Shinkeigaku; 2010 Nov; 50(11):794-6. PubMed ID: 21921444
[TBL] [Abstract][Full Text] [Related]
15. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
[TBL] [Abstract][Full Text] [Related]
16. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis.
Landau H; Hassoun H; Bello C; Hoover E; Riedel ER; Nimer SD; Comenzo RL
Amyloid; 2011 Jun; 18 Suppl 1():135-6. PubMed ID: 21838462
[No Abstract] [Full Text] [Related]
17. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
19. Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation.
Goto H; Nishio M; Kumano K; Fujimoto K; Yamaguchi K; Koike T
Bone Marrow Transplant; 2008 Nov; 42(9):627-9. PubMed ID: 18660839
[No Abstract] [Full Text] [Related]
20. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
